Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
This study is currently recruiting patients.
Sponsored by: | Memorial Sloan-Kettering Cancer Center |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die. 17-N-allylamino-17-demethoxygeldanamycin may also stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase II trial to study the effectiveness of 17-N-allylamino-17-demethoxygeldanamycin in treating patients who have metastatic kidney cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
recurrent renal cell cancer Stage IV Renal Cell Cancer renal clear cell carcinoma |
Drug: 17-N-allylamino-17-demethoxygeldanamycin Procedure: chemotherapy Procedure: enzyme inhibitor therapy Procedure: protein tyrosine kinase inhibitor therapy |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Kidney Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic Papillary or Clear Cell Renal Cell Carcinoma
OBJECTIVES: Primary
Secondary
OUTLINE: This is an open-label study. Patients are stratified according to histology (papillary vs clear cell).
Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-90 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Patients are followed at 3 weeks and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 24-74 patients (12-37 per stratum) will be accrued for this study within 6-20 months (clear cell stratum) and 2-5 years (papillary stratum).
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |